trending Market Intelligence /marketintelligence/en/news-insights/trending/uCYzzBtNEP-xHzCqgFbZcQ2 content esgSubNav
In This List

Prometic's lung disease drug gets US FDA orphan drug designation

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation

Blog

Using Credit Analytics to Avoid Mispricing Insurance Premiums

Blog

Post-Webinar Q&A: Integrating Climate Risks into Credit Risk Portfolios


Prometic's lung disease drug gets US FDA orphan drug designation

The U.S. Food and Drug Administration granted orphan drug status to ProMetic Life Sciences Inc.'s Ryplazim to treat idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis is a chronic, devastating, and ultimately fatal disease characterized by a progressive decline in lung function.

Prometic said this is the second orphan drug designation for its idiopathic pulmonary fibrosis pipeline after PBI-4050.